Arcus Biosciences Net Profit Margin Growth & History (RCUS)
Arcus Biosciences's net profit margin was −1,069.70% for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −1,069.70% | −514.80 pp |
| 2024 | 2024-12-31 | −554.90% | +274.83 pp |
| 2023 | 2023-12-31 | −829.73% | −127.10 pp |
| 2022 | 2022-12-31 | −702.63% | −716.47 pp |
| 2021 | 2021-12-31 | 13.84% | +171.53 pp |
| 2020 | 2020-12-31 | −157.69% | +407.04 pp |
| 2019 | 2019-12-31 | −564.73% | +28.99 pp |
| 2018 | 2018-12-31 | −593.73% | +3162.96 pp |
| 2017 | 2017-12-31 | −3,756.69% | — |
Arcus Biosciences quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −275.76% | −275.76 pp |
| Q1 2026 | 2026-03-31 | −1,828.57% | −428.57 pp |
| Q4 2025 | 2025-12-31 | −963.64% | −554.94 pp |
| Q3 2025 | 2025-09-30 | −2,250.00% | −935.71 pp |
| Q2 2025 | 2025-06-30 | 0.00% | +845.45 pp |
| Q1 2025 | 2025-03-31 | −1,400.00% | −1360.00 pp |
| Q4 2024 | 2024-12-31 | −408.70% | — |
| Q3 2024 | 2024-09-30 | −1,314.29% | −1092.41 pp |
| Q2 2024 | 2024-06-30 | −845.45% | −586.83 pp |
| Q1 2024 | 2024-03-31 | −40.00% | +280.00 pp |
| Q3 2023 | 2023-09-30 | −221.88% | −24.91 pp |
| Q2 2023 | 2023-06-30 | −258.62% | −10.47 pp |
| Q1 2023 | 2023-03-31 | −320.00% | +57.78 pp |
| Q3 2022 | 2022-09-30 | −196.97% | +627.20 pp |
| Q2 2022 | 2022-06-30 | −248.15% | +554.83 pp |
| Q1 2022 | 2022-03-31 | −377.78% | +389.51 pp |
| Q4 2021 | 2021-12-31 | 78.83% | +625.40 pp |
| Q3 2021 | 2021-09-30 | −824.17% | −827.00 pp |
| Q2 2021 | 2021-06-30 | −802.98% | +1772.68 pp |
| Q1 2021 | 2021-03-31 | −767.29% | +818.60 pp |
| Q4 2020 | 2020-12-31 | −546.57% | −376.33 pp |
| Q3 2020 | 2020-09-30 | 2.82% | +1280.08 pp |
| Q2 2020 | 2020-06-30 | −2,575.66% | −970.51 pp |
| Q1 2020 | 2020-03-31 | −1,585.89% | −576.17 pp |
| Q4 2019 | 2019-12-31 | −170.24% | +616.90 pp |
| Q3 2019 | 2019-09-30 | −1,277.26% | −1025.29 pp |
| Q2 2019 | 2019-06-30 | −1,605.14% | −522.50 pp |
| Q1 2019 | 2019-03-31 | −1,009.71% | +26.61 pp |
| Q4 2018 | 2018-12-31 | −787.13% | +269.67 pp |
| Q3 2018 | 2018-09-30 | −251.97% | +13933.31 pp |
| Q2 2018 | 2018-06-30 | −1,082.64% | — |
| Q1 2018 | 2018-03-31 | −1,036.32% | — |
| Q4 2017 | 2017-12-31 | −1,056.80% | — |
| Q3 2017 | 2017-09-30 | −14,185.28% | — |
Arcus Biosciences net profit margin trends
Over the last five fiscal years, Arcus Biosciences's net profit margin decreased from −157.69% to −1,069.70%, a change of −912.00 percentage points. The latest reported quarter, Q2 2026, shows −275.76%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗